ALLMedicine™ Atopic Dermatitis Center

Apr 14th, 2021 - Staphylococcus aureus has been associated with the exacerbation and severity of atopic dermatitis (AD). Studies have not investigated the colonisation dynamics of S. aureus lineages in African toddlers with AD. We determined the prevalence and pop...

Apr 14th, 2021 - Recent population-based data indicate that atopic dermatitis (AD) is associated with learning disability (LD) in children, but the association between AD severity and LD is unknown. To evaluate the association of AD severity with learning problems...

Apr 14th, 2021 - Atopic dermatitis (AD) may affect academic performance through multiple pathways, including poor concentration associated with itching, sleep deprivation, or adverse effects of medications. Because educational attainment is associated with health ...

Apr 14th, 2021 - Atopic Dermatitis and Academic Achievement-More to Learn.|2021|Abuabara K,|

Apr 14th, 2021 - Atopic dermatitis (AD) is a very common chronic inflammatory skin disease. Ustekinumab is a human monoclonal antibody approved for psoriasis, that targets the p40 subunit shared by interleukin (IL)-12 and IL-23, cytokines which may also play a rol...

Nov 4th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Jun 24th, 2019 - Atopic dermatitis is a chronic, itchy skin condition that is very common in children but may occur at any age. It is also known as eczema and atopic eczema and was formerly known as Besnier prurigo. It is the most common form of dermatitis. Atopi...

Jun 24th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Jun 3rd, 2019 - Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People ...

Mar 17th, 2019 - This clinical report updates and replaces a 2008 clinical report from the American Academy of Pediatrics, which addressed the roles of maternal and early infant diet on the prevention of atopic disease, including atopic dermatitis, asthma, and foo...

Apr 14th, 2021 - Staphylococcus aureus has been associated with the exacerbation and severity of atopic dermatitis (AD). Studies have not investigated the colonisation dynamics of S. aureus lineages in African toddlers with AD. We determined the prevalence and pop...

Apr 14th, 2021 - Recent population-based data indicate that atopic dermatitis (AD) is associated with learning disability (LD) in children, but the association between AD severity and LD is unknown. To evaluate the association of AD severity with learning problems...

Apr 14th, 2021 - Atopic dermatitis (AD) may affect academic performance through multiple pathways, including poor concentration associated with itching, sleep deprivation, or adverse effects of medications. Because educational attainment is associated with health ...

Apr 14th, 2021 - Atopic Dermatitis and Academic Achievement-More to Learn.|2021|Abuabara K,|

Apr 14th, 2021 - Atopic dermatitis (AD) is a very common chronic inflammatory skin disease. Ustekinumab is a human monoclonal antibody approved for psoriasis, that targets the p40 subunit shared by interleukin (IL)-12 and IL-23, cytokines which may also play a rol...

Apr 12th, 2021 - The American Academy of Pediatrics recently issued five recommendations for the most common dermatologic problems in primary care pediatrics. Topics include diagnostic and management strategies for a variety of conditions, including atopic dermati...

Apr 7th, 2021 - (Reuters) - Pfizer Inc said on Wednesday the U.S. Food and Drug Administration (FDA) had extended the review of its experimental atopic dermatitis drug by three months, the latest regulatory setback for a class of treatments known as JAK inhibitor...

Mar 24th, 2021 - An experimental oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, showed greater itch reduction after 2 weeks of treatment than dupilumab in patients with moderate to severe atopic dermatitis (AD), in a multicenter, randomized trial. An experimen...

Mar 23rd, 2021 - Ruxolitinib cream, an investigational selective Janus kinase 1 and 2 inhibitor now under priority review by the Food and Drug Administration for the treatment of atopic dermatitis (AD) down to age 12 years, demonstrated a dual mechanism of action ...

Mar 17th, 2021 - In patients with skin of color, atopic dermatitis appears with various clinical manifestations. Erythema may be difficult to see or may appear violaceous. Inflammation from atopic dermatitis may result in hypopigmentation or hyperpigmentation of t...